GlassScriptPhysician profile
Jami T Perry
NPI 1710050729
$3,348.83
in general payments reported to CMS, 2019-2025
27 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $128 · 2021: $115 · 2022: $333 · 2023: $349 · 2024: $850 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,615.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,183.34 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $301.01 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $284.02 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $180.48 | 2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $165.85 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $156.18 | 2019-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $128.63 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $121.85 | 2023-2025 | |
| Axsome Therapeutics, INC. | $87.57 | 2025 | Auvelity, Symbravo |
| Amarin Pharma, INC. | $81.47 | 2020-2021 | |
| Amgen INC. | $79.28 | 2020-2025 | Repatha, Otezla, Repatha |
| Ironshore Pharmaceuticals INC. | $62.70 | 2019 | |
| Merck Sharp & Dohme LLC | $62.03 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Alkermes, INC. | $61.24 | 2025 | Lybalvi |
| Biohaven Pharmaceutical Holding Company LTD. | $50.11 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $48.06 | 2025 | I-Stat, Eterna |
| Phathom Pharmaceuticals, INC. | $48.03 | 2024-2025 | Voquezna |
| Allergan, INC. | $46.54 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $37.72 | 2023-2024 | Qelbree, Qelbree |
| Dexcom, INC. | $35.96 | 2022-2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $29.83 | 2025 | Cobenfy |
| Globus Medical, INC. | $21.87 | 2025 | Senza |
| Lundbeck LLC | $16.42 | 2024 | Rexulti |
| Exact Sciences Corporation | $15.66 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.44 | 2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $13.88 | 2025 | Jornay Pm |
| Novartis Pharmaceuticals Corporation | $13.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jami Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.